Multiepitope fusion antigens and vaccines and their use in treatment of enterotoxigenic diarrhea
View Patent ↗Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STa- toxoid LT toxoid ). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.
1. A fusion polypeptide molecule which comprises the colonization factor antigen (CFA) antigenic epitopes of CFA/I (SEQ ID NO: 4), CFA/II (CS1 (SEQ ID NO: 5), CS2 (SEQ ID NO: 6), CS3 (SEQ ID NO: 7), CFA/IV (CS4 (SEQ ID NO: 8), CS5 (SEQ ID NO: 9), and CS6 (SEQ ID NO: 10), and wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1, or having at least 90% sequence identity to SEQ ID NO: 1.
2. A pharmaceutical composition comprising the fusion polypeptide molecule of claim 1 , and a pharmaceutically acceptable carrier.
3. A method for developing an immune response to colonization factor antigen (CFA) antigenic epitopes of CFA/I (SEQ ID NO: 4), CFA/II (CS1 (SEQ ID NO: 5), CS2 (SEQ ID NO: 6), CS3 (SEQ ID NO: 7), CFA/IV (CS4 (SEQ ID NO: 8), CS5 (SEQ ID NO: 9), and CS6 (SEQ ID NO: 10) in a subject comprising administering to the subject an effective amount of a polypeptide molecule consisting of the amino acid sequence of SEQ ID NO: 1.
4. The method of claim 3 , wherein the polypeptide is administered to the subject in a vaccine formulation.
5. The method of claim 3 , further comprising administration of at least one additional therapeutic agent.
6. The method of claim 5 , wherein the additional therapeutic agent is selected from the group consisting of: anti-motility, antidiarrheals, antibiotics, antihelminths, and anti-parasiticals.